| Marc J Michaud, MD | |
|
700 Lake Ave, Suite One, Manchester, NH 03103-2734 | |
| (603) 669-5454 | |
| (603) 641-0360 |
| Full Name | Marc J Michaud |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 31 Years |
| Location | 700 Lake Ave, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063491702 | NPI | - | NPPES |
| 30204355 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XX0004X | Orthopaedic Surgery - Foot And Ankle Surgery | 31401 (Arizona) | Secondary |
| 207XX0004X | Orthopaedic Surgery - Foot And Ankle Surgery | 12269 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Catholic Medical Center | Manchester, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Four Seasons Orthopaedic Center Pllc | 5193791804 | 41 |
News Archive
Carbon dioxide emissions from fossil fuel sources reached a maximum daily decline of 17 per cent in April as a result of drastic decline in energy demand that have occurred during the COVID-19 pandemic.
Researchers funded by the National Institutes of Health have developed a flexible brain implant that could one day be used to treat epileptic seizures. In animal studies, the researchers used the device - a type of electrode array that conforms to the brain's surface - to take an unprecedented look at the brain activity underlying seizures.
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
› Verified 5 days ago
| Entity Name | Four Seasons Orthopaedic Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881772242 PECOS PAC ID: 5193791804 Enrollment ID: O20040903000533 |
News Archive
Carbon dioxide emissions from fossil fuel sources reached a maximum daily decline of 17 per cent in April as a result of drastic decline in energy demand that have occurred during the COVID-19 pandemic.
Researchers funded by the National Institutes of Health have developed a flexible brain implant that could one day be used to treat epileptic seizures. In animal studies, the researchers used the device - a type of electrode array that conforms to the brain's surface - to take an unprecedented look at the brain activity underlying seizures.
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
› Verified 5 days ago
| Entity Name | Northeast Orthopaedic Alliance Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417724170 PECOS PAC ID: 5991149809 Enrollment ID: O20240223001001 |
News Archive
Carbon dioxide emissions from fossil fuel sources reached a maximum daily decline of 17 per cent in April as a result of drastic decline in energy demand that have occurred during the COVID-19 pandemic.
Researchers funded by the National Institutes of Health have developed a flexible brain implant that could one day be used to treat epileptic seizures. In animal studies, the researchers used the device - a type of electrode array that conforms to the brain's surface - to take an unprecedented look at the brain activity underlying seizures.
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marc J Michaud, MD 17 Riverside St, Suite 101, Nashua, NH 03062-1304 Ph: (603) 883-0091 | Marc J Michaud, MD 700 Lake Ave, Suite One, Manchester, NH 03103-2734 Ph: (603) 669-5454 |
News Archive
Carbon dioxide emissions from fossil fuel sources reached a maximum daily decline of 17 per cent in April as a result of drastic decline in energy demand that have occurred during the COVID-19 pandemic.
Researchers funded by the National Institutes of Health have developed a flexible brain implant that could one day be used to treat epileptic seizures. In animal studies, the researchers used the device - a type of electrode array that conforms to the brain's surface - to take an unprecedented look at the brain activity underlying seizures.
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
› Verified 5 days ago
Dr. Jason A Oliviero, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Paul J Scibetta Jr., DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 185 Queen City Ave, Manchester, NH 03101 Phone: 603-625-1655 Fax: 603-626-4686 | |
Dr. Mary-lee Sole, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 185 Queen City Ave, Elliot Orthopaedic Surgery Specialists, Manchester, NH 03101 Phone: 603-625-1655 Fax: 603-686-4686 | |
David H Gundy, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 700 Lake Ave, Suite One, Manchester, NH 03103 Phone: 603-669-5454 Fax: 603-641-0360 | |
Dr. Jonathan Eberhard Mack, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 185 Queen City Ave, Elliot Orthopaedic Surgery Specialists, Manchester, NH 03101 Phone: 603-625-1655 Fax: 603-626-4686 | |
Dr. Nicholas John Horangic, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 |